Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience.
Baidoun F, Chen D, Patnaik M, Gangat N, Begna K, Elliott M, Hogan W, Litzow M, Al-Kali A.
Leuk Lymphoma. 2019 Oct;60(10):2483-2487. doi: 10.1080/10428194.2019.1581930. Epub 2019 Mar 7.
PMID:31609151
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM, Zeidan AM.
Best Pract Res Clin Haematol. 2020 Jun;33(2):101132. doi: 10.1016/j.beha.2019.101132. Epub 2019 Dec 6.
PMID:32460977
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MA, Passweg J, Byrne J, Ho A, Huang XJ, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, McLornan DP, Onida F, Scheid C, Robin M, Yakoub-Agha I.
Bone Marrow Transplant. 2023 Feb;58(2):222-225. doi: 10.1038/s41409-022-01870-9. Epub 2022 Nov 19.
PMID:36402922
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.
Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A.
Am J Clin Pathol. 2017 Jul 1;148(1):49-57. doi: 10.1093/ajcp/aqx043.